Frontier investable areas in brain health with PsyMed Ventures
Feb 25, 2025•50 min•Season 1Ep. 63
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Matias and Greg sit down with Brooks Leitner, the newest venture partner at PsyMed Ventures, to explore the future of brain and mental health investing. Brooks, an MD/PhD with deep experience from Yale and the NIH, shares his insights on how a human-first approach is reshaping neuroscience innovation and venture investing.
In this episode, we discuss:
- Broadening the Thesis: Evolving from a psychedelics-only focus to a comprehensive neuro investment strategy.
- Human-First Research: Shifting from animal models to clinical insights for better brain therapies.
- Key Investment Areas: Therapeutics, medical devices, diagnostics, consumer health, and AI-enabled care platforms.
- Early-Stage Conviction: Leveraging a prepared mind to spot breakthrough opportunities.
- Personal & Future Insights: Leadership challenges and the vision for the future of neuro investing.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast